Curcumin in clinical practice: myth or reality?

Trends in Pharmacological Sciences

Volumn 30, Issue 7, 2009, Pages 333-334

  Mancuso, Cesare ^a   Barone, Eugenio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CURCUMINOID DERIVATIVE; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PIPERINE; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLITIS; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TARGETING; ENZYME METABOLISM; HEART PROTECTION; HUMAN; LETTER; LICHEN PLANUS; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

ANIMALS; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649407501     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.04.004     Document Type: Letter

References (13)

1. Aggarwal B.B., and Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30 (2009) 85-94
2. Mancuso C., et al. Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs 16 (2007) 1921-1931
3. Hayeshi R., et al. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol. 45 (2007) 286-295
4. Basu N.K., et al. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. 279 (2004) 1429-1441
5. Oetari S., et al. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochem. Pharmacol. 51 (1996) 39-45
6. Appiah-Opong R., et al. Inhibition of human recombinant cytochrome P450 s by curcumin and curcumin decomposition products. Toxicology 235 (2007) 83-91
7. Volak L.P., et al. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab. Dispos. 36 (2008) 1594-1605
8. Correia M.A. Drug biotransformation. In: Katzung B.G. (Ed). Basic and Clinical Pharmacology. 10th edn (2007), The McGraw-Hill Companies 50-63
9. Zhou S., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44 (2005) 279-304
10. Baum L., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28 (2008) 110-113
11. Baum L., et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 56 (2007) 509-514
12. Chainani-Wu N., et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 14 (2007) 437-446
13. Hanai H., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4 (2006) 1502-1506